Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC.

Autor:	Mc Leer A; Université Grenoble Alpes, Grenoble, France.; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France.; Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France., Mondet J; Université Grenoble Alpes, Grenoble, France.; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France.; Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France., Magnat N; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France., Mersch M; Université Grenoble Alpes, Grenoble, France.; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France., Giovannini D; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France.; TIMC-IMAG, Université Grenoble-Alpes, La Tronche, France., Emprou C; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France.; Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France., Toffart AC; Université Grenoble Alpes, Grenoble, France.; Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France.; Clinique Hospitalo-Universitaire de Pneumologie Physiologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France., Sturm N; Université Grenoble Alpes, Grenoble, France.; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France.; TIMC-IMAG, Université Grenoble-Alpes, La Tronche, France., Lantuéjoul S; Université Grenoble Alpes, Grenoble, France.; Cancer Research Center Lyon, Centre Léon Bérard, Lyon, France., Benito D; Medical Affairs - Oncology, Eli Lilly (Suisse) S.A., Dubai, United Arab Emirates.
Jazyk:	angličtina
Zdroj:	JTO clinical and research reports [JTO Clin Res Rep] 2024 Aug 29; Vol. 5 (12), pp. 100714. Date of Electronic Publication: 2024 Aug 29 (Print Publication: 2024).
DOI:	10.1016/j.jtocrr.2024.100714
Abstrakt:	Introduction: RET rearrangements occur in 1% to 2% NSCLCs. Since no clinically validated RET antibody is currently available, fluorescence in situ hybridization (FISH) is often used as a screening tool to identify patients likely to benefit from RET-targeted therapy. In this study, we performed a comprehensive review of publications in which RET -rearrangement testing was performed by FISH and compared the methods and results with our data. Methods: The findings of an electronic search for publications using RET -FISH in lung cancer were compared with the results obtained at the Grenoble University Hospital where 784 EGFR - , KRAS - , ALK -, and ROS1 -negative NSCLCs were tested by RET break-apart FISH and confirmed by RNA-sequencing (RNA-seq). Results: Out of the 85 publications using RET -FISH analysis, 52 pertained to patients with lung cancer. The most often used positivity threshold was 15%. Six publications compared RET -FISH with at least one other molecular technique on at least eight samples, and the concordance was variable, from 5.9% to 66.7% for FISH-positive cases. Regarding our data, out of the 784 analyzed samples, 32 (4%) were positive by RET -FISH. The concordance between RET -FISH and RNA-seq in RET -FISH positive samples was 69%. Conclusions: Overall, both existing literature and our data suggest that RET -FISH testing can be used for rapid screening of RET rearrangements in NSCLC. Nevertheless, using an orthogonal technique such as RNA-seq to confirm RET -FISH-positive cases is essential for ensuring that only patients likely to benefit from RET -target therapy receive the treatment. Competing Interests: Dr. Mc Leer has declared consulting fees from 10.13039/100015756Janssen-Cilag, Eli Lilly, Takeda, JFR Access, Pfizer, payment for presentations from Amgen, AstraZeneca, Cancerodigest, Edimark, Janssen-Cilag and support for attending meetings from Amgen, AstraZeneca, Janssen-Cilag, Pfizer. Dr. Toffart has declared consulting fees from 10.13039/100004325AstraZeneca, 10.13039/100002491Bristol-Myers Squibb, 10.13039/100002429Amgen, 10.13039/501100014382Ipsen, Janssen, 10.13039/100009947Merck Sharp & Dohme, 10.13039/100004319Pfizer, 10.13039/100004337Roche, Sanofi, Takeda, payment for presentations from AstraZeneca, Bristol-Myers Squibb, Amgen, Ipsen, Janssen, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, Takeda, payment for expert testimony from AstraZeneca, Bristol-Myers Squibb, Amgen, Ipsen, Janssen, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, Takeda and support for attending meetings from AstraZeneca, Pfizer, Roche, Takeda. Dr. Benito is a full-time employee at Eli Lilly Co. The remaining authors declare no conflict of interest. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu